Loading
Lists of recommended off-label and on-label drug uses that US insurers, including Medicare, use to decide what to pay for.
The NCCN Compendium and the other drug compendia are lists of recommended on-label and off-label drug uses that US insurers, including Medicare, consult when deciding what to pay for. The NCCN Drugs & Biologics Compendium, alongside Micromedex, Lexicomp and Clinical Pharmacology, is recognised by CMS, so a Category 1 or 2A listing generally secures coverage even when the FDA label does not include that indication. This gives guideline panels de facto power over reimbursement and explains the term's link to Standard of care and to Label, indication and label expansion. It is tied to the Oncology EHR modules and treatment pathways technology and features in cost ideas on prior authorisation exemptions and real-time prior authorisation from the medical record.
Showing the technology this term belongs to: Oncology EHR modules and treatment pathways.
Shares Answer prior authorisation requests in seconds from the medical record, Oncology EHR modules and treatment pathways.
Shares Exempt oncologists who follow the pathway from prior authorisation, Standard of care.
Shares Medicare coverage with evidence development, Standard of care.
Shares Label, indication and label expansion, Medicare coverage with evidence development.